A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome
Completed · Phase 3 · Has a placebo group
Conditions studied: Familial Chylomicronemia Syndrome (FCS)
In brief
The purpose of this study is to determine whether LCQ908 is effective and safe in lowering triglycerides in subjects with Familial Chylomicronemia Syndrome (FCS) (Hyperlipoproteinemia \[HLP\] type I). Data from this study will be used to support a registration submission of LCQ908 20 mg and 40 mg as treatment of chylomicronemia in subjects with FCS (HLP Type 1).
Key facts
- Study ID
- NCT01514461
- Run by
- Novartis Pharmaceuticals
- People needed
- 45
- Starts
- 2012-07-01
- Expected to finish
- 2014-05-01
- Last updated by the study team
- 2015-06-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Seatlle, Washington, United States
- Novartis Investigative Site — Chicoutimi, Quebec, Canada
- Novartis Investigative Site — Ste-Foy, Quebec, Canada
- Novartis Investigative Site — Ouest-Montreal, Canada
- Novartis Investigative Site — Bron, France
- Novartis Investigative Site — Nantes, France
- Novartis Investigative Site — Paris, France
- Novartis Investigative Site — Cologne, Germany
- Novartis Investigative Site — Hamburg, Germany
- Novartis Investigative Site — Meibergdreef 9, Netherlands
- Novartis Investigative Site — Cape Town, South Africa
- Novartis Investigative Site — Málaga, Andalusia, Spain
- Novartis Investigative Site — Seville, Andalusia, Spain
- Novartis Investigative Site — Manchester, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.